BridgeMD
New treatment option for Nasopharyngeal Carcinoma
Official title 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
ClinicalTrials.gov ID: NCT04813705
What this study is testing
What is Chemotherapy?
Chemotherapy is an investigational medicine, being studied as a potential treatment for nasopharyngeal carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Pathology confirmed nasopharyngeal squamous cell carcinoma.
- Stage I-IVA（8thAJCC/UICC staging system).
- Aged 18-80 years.
- KPS≥70.
- Have measurable lesions on 18F-FDG PET/CT before treatment.
You likely can't join if
- Past malignancies history (except for stage I non-melanoma skin cancer or cervical carcinoma in situ).
- Age \ 80years.
- Pregnancy or lactation.
- History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).
- Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.
- With sever infection and internal disease.
See the full eligibility criteria
- Pathology confirmed nasopharyngeal squamous cell carcinoma.
- Stage I-IVA（8thAJCC/UICC staging system).
- Aged 18-80 years.
- KPS≥70.
- Have measurable lesions on 18F-FDG PET/CT before treatment.
- HGB≥90 g/L，ANC≥1.5×109 /L，PLT≥80×109 /L.
- ALT,AST\<2.5 fold of ULN；TBIL\<2.0×ULN.
- CCR≥60ml/min or Cr\<1.5×ULN.
- Signed informed consent.
- Have follow up condition.
- Past malignancies history (except for stage I non-melanoma skin cancer or cervical carcinoma in situ).
- Age \ 80years.
- Pregnancy or lactation.
- History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).
- Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.
- With sever infection and internal disease.
- Major organ dysfunction, such as decompensated cardiopulmonary, kidney, liver failure, cannot tolerate surgical treatment.
The study team makes the final eligibility decision.
Where it's taking place
- Taizhou, Zhejiang, China
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taizhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.